



- (51) **International Patent Classification:**
A01N 43/42 (2006.01) *A61K 31/44* (2006.01)
- (21) **International Application Number:**
PCT/US2012/043687
- (22) **International Filing Date:**
22 June 2012 (22.06.2012)
- (25) **Filing Language:** English
- (26) **Publication Language:** English
- (71) **Applicant** (for all designated States except US): **MAP PHARMACEUTICALS, INC.** [US/US]; 2400 Bayshore Parkway, Suite 200, Mountain View, CA 94043 (US).
- (72) **Inventors; and**
- (75) **Inventors/Applicants** (for US only): **ZHANG, Jian** [CN/US]; 2400 Bayshore Parkway, Suite 200, Mountain View CA 94043 (GB). **ARMER, Thomas, A.** [US/US]; 2400 Bayshore Parkway, Suite 200, Mountain View, CA 94043 (US).
- (74) **Agent:** **CHENG, Jennifer, C.**; Map Pharmaceuticals, Inc., 2400 Bayshore Parkway, Suite 200, Mountain View, CA 94043 (US).

- (81) **Designated States** (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.
- (84) **Designated States** (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

Published:
— with international search report (Art. 21(3))

(54) **Title:** NOVEL CABERGOLINE DERIVATIVES

(57) **Abstract:** Provided herein are novel cabergoline analogs and compositions thereof. In other embodiments, provided herein are methods of treatment, prevention, or amelioration of a variety of medical disorders such as, for example, migraine and Parkinson's disease using the compounds and compositions disclosed herein. In still other embodiments, provided herein are methods of agonizing dopaminergic D₂ receptors and/or antagonizing or inhibiting activity of receptors such as the 5-HT₂ serotonin receptors using the compounds and compositions disclosed herein. In still other embodiments, provided herein are methods of agonizing receptors such as, for example, the 5-HT_{1D} and/or the 5-HT_{1B} receptor, without agonizing (or very weakly agonizing) the 5-HT_{2B} receptor using the compounds and compositions disclosed herein.



WO 2013/191704 A1